prikaz prve stranice dokumenta Benigna hiperplazija prostate - medikamentozno liječenje
  Download
PDF 1.21 MB
Scientific paper - Review paper
Benigna hiperplazija prostate - medikamentozno liječenje
Medicina Fluminensis : Medicina Fluminensis, 53 (2017), 3; 273-284. https://doi.org/10.21860/medflum2017_182960
Markić, Dean; Kaštelan, Željko; El-Saleh, Ahmad; Španjol, Josip

Cite this document

Markić, D., Kaštelan, Ž., El Saleh, A. & Španjol, J. (2017). Benigna hiperplazija prostate - medikamentozno liječenje. Medicina Fluminensis : Medicina Fluminensis, 53. (3), 273-284. doi: 10.21860/medflum2017_182960

Markić, Dean, et al. "Benigna hiperplazija prostate - medikamentozno liječenje." Medicina Fluminensis : Medicina Fluminensis, vol. 53, no. 3, 2017, pp. 273-284. https://doi.org/10.21860/medflum2017_182960

Markić, Dean, Željko Kaštelan, Ahmad El Saleh and Josip Španjol. "Benigna hiperplazija prostate - medikamentozno liječenje." Medicina Fluminensis : Medicina Fluminensis 53, no. 3 (2017): 273-284. https://doi.org/10.21860/medflum2017_182960

Markić, D., et al. (2017) 'Benigna hiperplazija prostate - medikamentozno liječenje', Medicina Fluminensis : Medicina Fluminensis, 53(3), pp. 273-284. doi: 10.21860/medflum2017_182960

Markić D, Kaštelan Ž, El Saleh A, Španjol J. Benigna hiperplazija prostate - medikamentozno liječenje. Medicina Fluminensis : Medicina Fluminensis [Internet]. 2017 September 01 [cited 2024 November 26];53(3):273-284. doi: 10.21860/medflum2017_182960

D. Markić, Ž. Kaštelan, A. El Saleh and J. Španjol, "Benigna hiperplazija prostate - medikamentozno liječenje", Medicina Fluminensis : Medicina Fluminensis, vol. 53, no. 3, pp. 273-284, September 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:504494. [Accessed: 26 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (croatian)Benigna hiperplazija prostate - medikamentozno liječenje
Title (english)Benign prostatc hyperplasia – medicamentous treatment
AuthorDean Markić
AuthorŽeljko Kaštelan
AuthorAhmad El-Saleh
AuthorJosip Španjol
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Urology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Urology
Abstract (croatian)
Benigna hiperplazija prostate (BPH) karakterizirana je umnažanjem žljezdanih i/ili stromalnih elemenata prostate. Ona može dovest do uvećanja prostate i uzrokovati smetnje mokrenja donjeg dijela mokraćnog sustava (LUTS). Rast prostate ovisan je o dobi i utjecaju spolnih hormona, prvenstveno dihidrotestosterona. Simptomi se dijele na iritatvne, opstruktvne i postmikcijske. U osnovnu obradu pacijenata spada anamneza, korištenje upitnika o smetnjama mokrenja, dnevnik mokrenja, fizikalni pregled, analiza urina, serumska koncentracija kreatinina i prostata specifčnog antigena, mikciometrija i mjerenje rezidualnog urina. Terapiju se odabire na osnovi smetnji koje pacijent ima i rezultata dijagnostčke obrade. Prvi korak u liječenju predstavljaju određene promjene u ponašanju i prehrani. U pacijenata s blagim smetnjama preporučuje se aktivno praćenje. U ostalih pacijenata započinje se s medikamentoznom terapijom. Mogućnost medikamentozne terapije su mnogobrojne: blokatori alfa adrenergičkih receptora, inhibitori 5-alfa-reduktaze, antagonisti muskarinskih receptora, analog vazopresina – dezmopresin, agonisti beta-3 adrenergičkih receptora, inhibitori 5-fosfodiesteraze, fitoterapija i kombinirana terapija. U slučaju neuspjeha medikamentozne terapije ili prisutnost komplikacija BPH-a preporučuje se kirurško liječenje.
Abstract (english)
Benign prostatic hyperplasia (BPH) is characterized with proliferaton of glandular and stromal components of the prostate. BPH can produce prostate enlargement and caused lower urinary tract symptoms (LUTS). The growth of the prostate depends on patent’s age and influence of sexual hormones, specially dihydrotestosterone. Symptoms can be divided as irritatve, obstructve and postmicturation symptoms. The basic evaluation included medical history, symptom score questionnaire, bladder diary, physical examinaton, urinalysis, creatinine and prostate specific antigen serum concentraton, uroflowmetry and postvoid residual urine. The modality of treatment depends about patents symptoms and results of diagnostic evaluaton. The inital step in the treatment are behavioural and dietary modificatons. In the patients with mild symptoms watchful waiting is first line treatment. In the other patients medicamentous treatment is recommended. Pharmacological management included: alpha adrenoreceptor antagonists, 5-alpha-reductase inhibitors, muscarin receptors antagonists, vasopressin analogue – desmopressin, beta-3 agonists, phosphodiesterase 5 inhibitors, phytotherapy and combinaton therapy. If the medicamentous therapy failed or the complicatons of BPH are present surgical treatment is recommended.
Keywords (croatian)
Keywords (english)
Languagecroatian
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMedicina Fluminensis : Medicina Fluminensis
Numberingvol. 53, no. 3, pp. 273-284
p-ISSN0025-7729
DOIhttps://doi.org/10.21860/medflum2017_182960
URN:NBNurn:nbn:hr:184:504494
Publication2017-09-01
Document URLhttp://hrcak.srce.hr/184831
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2017-09-05 10:19:18